# SEED Therapeutics

Source: https://onco.cc/companies/seed-therapeutics/  
OnCo record `seed-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

SEED Therapeutics designs molecular glues, tablet drugs that make the cell's own disposal system destroy a chosen protein. Its first cancer drug, ST-01156, removes a protein called RBM39 and is in an early trial for advanced solid tumours, including Ewing sarcoma and liver cancer.

## Summary

SEED Therapeutics, Inc., at 411 Swedeland Road, King of Prussia, Pennsylvania, develops rationally designed molecular glue degraders with its RITE3 platform, which it says gives access to more than 600 human E3 ubiquitin ligases rather than the two most used in the field. It was co-founded by Nobel laureate Avram Hershko, chief executive and chair Lan Huang (co-founder and chair of BeyondSpring), Ning Zheng of the University of Washington and Michele Pagano of New York University, and lists partnerships with Lilly and Eisai. Its lead programme ST-01156 is an oral, brain-penetrant RBM39 molecular glue degrader in a first-in-human phase 1/1b study in advanced solid malignancies, with a focus on RBM39-dependent cancers such as Ewing sarcoma, hepatocellular carcinoma and biliary tract cancer; the company presented the trial at ASCO in June 2026 and preclinical neuroblastoma data at AACR 2026. The pipeline also includes tau and mutant huntingtin degraders for neurodegeneration and an immunology programme. Its first registered cancer trial, NCT07197554, was posted on ClinicalTrials.gov in September 2025.

## Fields

- Kind: Company
- Last checked: 2026-10-29
- Also known as: SEED Therapeutics, Inc.
- HQ: King of Prussia, PA
- Type: biotech
- Website: https://seedtherapeutics.com/

## Notes

- Founding year not stated on the company website.
- The company was nominated for the Prix Galien USA Best Start-Up award in 2025 and 2026.
- Financing and any ownership stake held by BeyondSpring were not confirmed from a source read, so no funding rows or relationship are recorded.
- The registry contact domain oncodrugs.com did not serve a website; the company site is seedtherapeutics.com.
- Company website and August 2026 release read on 29 October 2026.

## Sources

- Official website: https://seedtherapeutics.com/
- Prix Galien nomination and ST-01156 update, August 2026: https://seedtherapeutics.com/media/seed-therapeutics-nominated-for-2026-prix-galien-usa-best-start-up-award
- ClinicalTrials.gov: phase 1/1b study of ST-01156, an RBM39 degrader (NCT07197554): https://clinicaltrials.gov/study/NCT07197554

## Connected records

- cancers: [Biliary tract cancer (all types)](https://onco.cc/cancers/biliary-tract-cancer/), [Ewing sarcoma](https://onco.cc/cancers/ewing-sarcoma/), [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/), [Neuroblastoma (paediatric)](https://onco.cc/cancers/neuroblastoma/)
- fronts: [Drug Discovery Platforms](https://onco.cc/fronts/drug-discovery/), [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- technologies: [Molecular glue discovery platforms](https://onco.cc/technologies/molecular-glue-platforms/), [PROTACs & molecular glues (targeted protein degradation)](https://onco.cc/technologies/protac-degrader/)
- targets: [RBM39](https://onco.cc/targets/rbm39/)

---
JSON: https://onco.cc/api/v1/entities/seed-therapeutics.json